MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
AcelRx Pharmaceuticals General and Administrative Expenses 2011-2026 | ACRX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.48 M | 8.53 M | 12 M | 17 M | 30.9 M | 36.3 M | 45 M | 20.8 M | 16.6 M | 15.6 M | 14.2 M | 18.3 M | 9.88 M | 7.2 M | 6.8 M | 3.99 M | 3.53 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45 M | 3.53 M | 16.1 M |
Quarterly General and Administrative Expenses AcelRx Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.3 M | 1.62 M | 2.19 M | 1.77 M | - | 1.7 M | 2.36 M | 2.8 M | - | 2.25 M | 2.67 M | 4.28 M | - | 3.72 M | 3.96 M | 4.1 M | - | 8.64 M | 8.69 M | 7.64 M | - | 7.6 M | 7.58 M | 13.3 M | - | 10.9 M | 11.3 M | 9.98 M | - | 5.19 M | 3.94 M | 3.98 M | - | 4.41 M | 4.16 M | 4.14 M | - | 4.14 M | 3.6 M | 3.78 M | - | 2.93 M | 2.74 M | 4.52 M | - | 4.65 M | 5.05 M | 3.92 M | - | 2.31 M | 2.07 M | 2.19 M | - | 1.41 M | 1.78 M | 2.1 M | - | 1.87 M | 1.63 M | 1.59 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 M | 1.41 M | 4.34 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
568 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
15.1 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.9 M | $ 5.61 | -1.06 % | $ 83.3 M | USA |
 |
HEXO Corp.
HEXO
|
32.9 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
390 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
DURECT Corporation
DRRX
|
10.5 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
138 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
18.5 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
42 M | $ 2.67 | 2.69 % | $ 1.02 B | Canada |
 |
Athenex
ATNX
|
44.9 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
153 M | $ 41.94 | 9.22 % | $ 1.54 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
181 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
935 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
107 M | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
294 M | $ 22.64 | -0.79 % | $ 1.05 B | USA |
 |
Organogenesis Holdings
ORGO
|
326 M | $ 2.34 | -2.5 % | $ 297 M | USA |
 |
Canopy Growth Corporation
CGC
|
160 M | $ 0.94 | -1.49 % | $ 280 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
7.6 M | $ 1.15 | 4.55 % | $ 1.94 M | USA |
 |
Aurora Cannabis
ACB
|
97.3 M | $ 2.92 | -2.67 % | $ 160 M | Canada |
 |
Solid Biosciences
SLDB
|
38.9 M | $ 7.31 | 3.39 % | $ 640 M | USA |
 |
Jupiter Wellness
JUPW
|
35.7 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
81 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
19.1 M | $ 0.99 | -2.26 % | $ 94.3 M | Canada |
 |
Tilray
TLRY
|
165 M | $ 4.75 | -2.66 % | $ 2.94 B | Canada |
 |
Veru
VERU
|
19.9 M | $ 2.99 | -4.47 % | $ 43.8 M | USA |
 |
Evolus
EOLS
|
221 M | $ 6.74 | 1.66 % | $ 435 M | USA |
 |
Sundial Growers
SNDL
|
38.4 M | $ 1.44 | 0.7 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
186 M | $ 8.14 | 5.03 % | $ 435 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
28.3 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
69 M | $ 23.5 | - | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
19.3 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
131 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
3.44 B | $ 4.76 | -3.94 % | $ 1.77 B | Canada |
 |
PetIQ
PETQ
|
196 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
32.2 M | $ 6.6 | 0.76 % | $ 261 M | USA |
 |
Recro Pharma
REPH
|
21 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
83.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
14.4 M | $ 3.8 | -7.09 % | $ 190 M | USA |
 |
PLx Pharma
PLXP
|
40 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
3.79 B | $ 15.73 | -1.93 % | $ 18.3 B | USA |
 |
Zomedica Corp.
ZOM
|
24.5 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.2 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
14 M | $ 0.65 | -3.93 % | $ 23.4 M | USA |
 |
Tricida
TCDA
|
37.6 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
2.45 M | $ 0.84 | 8.65 % | $ 3.6 M |  China |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 2.27 | -0.87 % | $ 26.3 M | USA |